SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have two oral presentations, one of which is late-breaking, during the International Society for Respiratory Viruses (ISRV) 8th AntiViral Group (AVG) Meeting and 3rd International Meeting on Respiratory Pathogens (IMRP). The conference is taking place September 17-20, 2025, in Singapore.
Presentation details are summarized below:
Late-Breaking Abstract Title: NAVIGATE: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Dose-ranging Trial to Evaluate the Efficacy and Safety of CD388 for Prevention of Influenza Illness in Healthy Adults
Presenter: Rick Bright, Ph.D. Bright Global Health, Cidara Therapeutics
Session: AVG Session 3
Session Date and Time: Wednesday, September 17, 2025, 3:50 – 4:05 p.m. SGT
Abstract Title: A Single Prophylactic dose of CD388 Provides Protection Against Highly Pathogenic Bovine-Origin Influenza A (H5N1) Virus in the Ferret Model
Presenter: Andreev Konstantin, Ph.D. St. Jude Children’s Research Hospital
Session: Parallel Session 2 (Track 1)
Session Date and Time: Friday, September 19, 2025, 10:30 a.m. – 12:30 p.m. SGT
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
This email address is being protected from spambots. You need JavaScript enabled to view it.
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
(628) 234-3889
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$64.85 |
| Daily Change: | 0.04 0.06 |
| Daily Volume: | 607,457 |
| Market Cap: | US$1.640B |
September 17, 2025 August 07, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
